LAURUSLABS Q4 FY25 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,720 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Laurus Labs delivered a strong FY25 with revenue of INR 5,554 crore (10% YoY) and PAT of INR 358 crore (122% YoY), driven by robust CDMO momentum and improved operating leverage. EBITDA margins expanded 400bps to 20.1%, reflecting better asset utilization and favorable product mix. The CDMO segment demonstrated exceptional performance with small molecule revenues growing 49% for FY25, supported by 110+ active projects (up from ~60 two years ago), with majority in Phase 2/3. The company is pivoting strategically—ARV revenue share declining from 67% to 45% over five years while CDMO share expanded from 13% to 28%. FY26 guidance indicates continued margin improvement as CDMO contribution rises, with ~INR 1,000 crore CapEx planned. Key risks include tariff uncertainty (though management sees minimal near-term impact), working capital pressures from complex CDMO projects, and modest ARV growth outlook at ~INR 2,500 crore range amid potential USAID funding concerns.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects significant growth in both revenues and profits for FY2026 compared to FY2025, driven by CDMO expansion and better asset utilization.
- Operating margins expected to improve from better asset utilization and favorable product mix as CDMO contribution increases.
- CapEx guidance of ~INR 1,000 crore for FY26, primarily for formulation CMO expansion, fermentation facility (INR 250 crore in Visakhapatnam), and API/CDMO production blocks.
- Non-ARV formulation revenue will increase from Q3 onwards due to new US/Canada approvals and CMO partner expansion commissioning in Q4 CY25.
Risks flagged
- Analyst raised concerns about potential impact of USAID funding pauses on ARV business. Management confirmed ~20% exposure (INR 250 crore) in formulation business to US-funded programs globally but expects limited near-term impact as inquiries continue for treatment (not PrEP).
- Analyst specifically questioned receivables increase. Management attributed this to longer order-to-delivery cycles for complex CDMO projects and higher logistics lead times for US/Canada formulation sales. Receivables at INR 2,000 crore vs Q4 revenue of INR 1,750 crore raised concerns.
- Analyst questioned China supply chain risks and tariff impacts. Management declined to comment specifically, stating it's too early to assess. Acknowledged some partners request avoidance of certain sources but cannot fully de-risk indirect KSM/intermediate dependencies on China currently.
- Asset turnover at 0.83x vs historical 1.1x suggests significant underutilization of INR 3,200 crore CapEx deployed over FY22-FY25. Management avoided committing to timeline for recovery, noting it depends on project scale and complexity progression.
Key quotes
- The growth was mainly driven by several mid to late-stage molecule deliveries and a steady increase in sales from new manufacturing assets, which was brought online during the second half of this year. CDMO pipeline momentum has remained healthy across clinical and commercial phase.
- As the CDMO revenues contribution goes up, we expect margins should also improve.
- I think your point and observation is very, very valid. If you look at the ROSI numbers, we were there earlier. It's not that we never had that number. It will take a few years for us to get there again.
Research modules